Robert Sibilia, MD
Pulmonary Disease · Wooster, OHNPI 1487620910
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 249 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$786
- GSK$574
- Jazz Pharmaceuticals Inc.$495
- AstraZeneca$442
- Sanofi$336
- Harmony Biosciences LLC$268
- plus $2K from 26 others
Across 27 payments — averaging $2278.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hikma Pharmaceuticals USA$38K
- Philips North America LLC$9K
- AstraZeneca$8K
- GSK$4K
- Pfizer$1K
- Actelion Pharmaceuticals, Ltd$800
What the payments were for
- Food & beverage$4,11190%
- Education$45010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 42 | $786 |
| GSK | 48 | $574 |
| Jazz Pharmaceuticals Inc. | 23 | $495 |
| AstraZeneca | 27 | $442 |
| Sanofi | 14 | $336 |
| Harmony Biosciences LLC | 6 | $268 |
| Actelion Pharmaceuticals US, Inc. | 12 | $263 |
| Boehringer Ingelheim | 13 | $210 |
| Grifols USA, LLC | 9 | $133 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Electromed, Inc. | 8 | $85 |
| Mylan Specialty L.p. | 5 | $83 |
| Bayer | 4 | $75 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $70 |
| Amgen | 4 | $67 |
| Insmed, Inc. | 3 | $64 |
| Inspire Medical Systems, Inc. | 2 | $63 |
| Baxter Healthcare | 3 | $50 |
| Medtronic | 3 | $43 |
| Merck | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $32 |
| Optinose US, Inc. | 1 | $26 |
| Boston Scientific | 1 | $22 |
| Getinge USA Sales, LLC | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$108
How this compares
$4,561 in reported general payments places this provider in the 65th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 59 | $1,403,192 |
| OfevNintedanib Esylate | 28 | $356,431 |
| OpsumitMacitentan | 23 | $318,064 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 285 | $239,882 |
| XywavSodium,calcium,mag,pot Oxybate | 13 | $201,115 |
| Breo ElliptaFluticasone/Vilanterol | 262 | $139,195 |
| Arnuity ElliptaFluticasone Furoate | 167 | $57,255 |
| Spiriva HandihalerTiotropium Bromide | 25 | $23,213 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 106 | $14,257 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $11,585 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $11,342 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,437 |
| BelsomraSuvorexant | 14 | $6,285 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 16 | $5,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $574 | $459,259748 claims |
| Boehringer IngelheimOfev | $210 | $356,43128 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $263 | $318,06423 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $442 | $15,34023 claims |
| MerckBelsomra | $41 | $6,28514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Wooster
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
- Jean ElwingCincinnati$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.